Re-thinking ‘community’ in the implementation of long-acting injectable Cabotegravir and Rilpivirine: qualitative findings from the ILANA study

AUTHORS

R. Hayes¹, S. Paparini¹, C. Mwendera², C.M. Orkin^3,4


INSTITUTIONS

¹Queen Mary University of London, SHARE Collaborative, Wolfson Institute for Population Health, London, United Kingdom, ²University of Liverpool, Clinical Infection, Microbiology & Immunology, Liverpool, United Kingdom, ³Queen Mary University of London, SHARE Collaborative, Blizard Institute, London, United Kingdom, ⁴Barts Health NHS Trust, Department of Infection and Immunity, London, United Kingdom